Puretech Health PLC (PRTC) Earns Buy Rating from Numis Securities Ltd
Puretech Health PLC (LON:PRTC)‘s stock had its “buy” rating restated by investment analysts at Numis Securities Ltd in a report issued on Monday. They presently have a GBX 207 ($2.79) price target on the stock. Numis Securities Ltd’s price target would suggest a potential upside of 56.82% from the company’s previous close.
PRTC has been the topic of a number of other reports. Jefferies Group LLC reissued a “buy” rating and set a GBX 255 ($3.44) price objective on shares of Puretech Health PLC in a research report on Friday, June 9th. Liberum Capital reissued a “buy” rating and set a GBX 248 ($3.34) price objective on shares of Puretech Health PLC in a research report on Wednesday, August 30th. N+1 Singer reissued a “buy” rating on shares of Puretech Health PLC in a research report on Wednesday, August 30th. Finally, Peel Hunt reissued a “buy” rating and set a GBX 259 ($3.49) price objective on shares of Puretech Health PLC in a research report on Monday. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of GBX 239 ($3.22).
Shares of Puretech Health PLC (LON PRTC) opened at 134.00 on Monday. The firm has a 50-day moving average of GBX 135.84 and a 200-day moving average of GBX 123.36. Puretech Health PLC has a 12-month low of GBX 110.00 and a 12-month high of GBX 165.00. The firm’s market capitalization is GBX 316.72 million.
About Puretech Health PLC
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.